Zevra Therapeutics, Inc. (ZVRA) Tops Q4 EPS by 53c
Tweet
Share
E-mailGet Alerts ZVRA Hot Sheet
Join SI Premium – FREE
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q4 EPS of $0.60, $0.53 better than the analyst estimate of $0.07. Revenue for the quarter came in at $36.2 million versus the consensus estimate of $31.96 million.
For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
- JPMorgan Upgrades Reckitt Benckiser (RKT:LN) (RBGLY) to Overweight
- GrafTech to permanently close Monterrey graphite electrode plant
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
